The Journey for Lung Cancer Screening where we Stand Today
Ali S. Wahla1, *, Zaid Zoumot1, Mateen Uzbeck1, Jihad Mallat1, Redha Souilamas1, Irfan Shafiq1
Identifiers and Pagination:Year: 2022
E-location ID: e187430642207060
Publisher ID: e187430642207060
Article History:Received Date: 12/1/2022
Revision Received Date: 21/2/2022
Acceptance Date: 19/4/2022
Electronic publication date: 05/09/2022
Collection year: 2022
open-access license: This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: https://creativecommons.org/licenses/by/4.0/legalcode. This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Lung cancer remains a leading cause of cancer mortality worldwide with many patients presenting with advanced disease.
We reviewed the available literature for lung cancer screening using low dose computed tomography (LDCT). We reviewed the National Lung Screening Trial (NLST), Early Lung Cancer Action Program (ELCAP) and the (Nederlands–Leuvens Longkanker Screenings Onderzoek (NELSON) trials. We also look at different lung cancer risk prediction models that may aid in identifying target populations and also discuss the cost-effectiveness of LDCT screening in different groups of smokers and ex-smokers. Lastly, we discuss recent guideline changes that have occurred in line with new and emerging evidence on lung cancer screening.
LDCT has been shown reduce lung cancer mortality in certain groups of current and former smokers and should be considered to help in the early diagnosis of lung cancer.